Content area
Full Text
In patients receiving vedolizumab for inflammatory bowel disease (IBD), severe spondyloarthropathy (SpA)-related enthesitis or osteitis may occur, according to an analysis of 11 patients reported in Rheumatology.
The 11 patients, comprising 6 women and 5 men with a mean age of 42.5 years, were identified from 7 centres. Nine patients developed de novo SpA, with 2 patients experiencing a flare of known SpA; 4 patients required hospitalisation. The median time to the development of inflammatory spinal symptoms was 12...